ECTRIMS: Roche's Ocrevus, given early, cuts wheelchair risk by 42%

Discussion in 'Pharma/Biotech Companies - In the News' started by cafead, Sep 15, 2019 at 10:02 PM.

  1. #1 cafead, Sep 15, 2019 at 10:02 PM
    cafead

    cafead Administrator
    Staff Member

    Joined:
    Nov 21, 2001
    Messages:
    33,028
    Likes Received:
    3
    via Roche is steamrolling with Ocrevus, which has quickly become the top-prescribed drug for new multiple sclerosis patients. And to maintain that lead, its touting long-term data that show the earlier it’s given, the better patients do.

    article source
     
    Quote

Reply to Thread